Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 14, Number 7—July 2008
Research

Toxinotype V Clostridium difficile in Humans and Food Animals

Michael A. Jhung*Comments to Author , Angela D. Thompson*, George E. Killgore*, Walter E. Zukowski†, Glenn Songer‡, Michael Warny§, Stuart Johnson†¶, Dale N. Gerding†¶, L. Clifford McDonald*, and Brandi M. Limbago*
Author affiliations: *Centers for Disease Control and Prevention, Atlanta, Georgia, USA; †Hines Veterans Affairs Hospital, Chicago, Illinois, USA; ‡University of Arizona, Tucson, Arizona, USA; §Acambis, Inc., Cambridge, Massachusetts, USA; ¶Loyola University Chicago Stritch School of Medicine, Chicago;

Main Article

Table 2

Antimicrobial drug susceptibility of toxinotype V Clostridium difficile isolates, 1989–2006*

Source N Clindamycin
Levofloxacin†
Moxifloxacin
Gatifloxacin†
S I/R Range S I/R Range S Range S Range
Human 14 2 (14) 12 (86) 2–>256 6 (43) 8 (57) 2–>32 14 (100) 0.5–1 14 (100) 0.5–1
Recent 7 2 (29) 5 (71) 2–>256 0 7 (100) >32 7 (100) 0.5 7 (100) 0.5–1
Past
7
0
7 (100)
4–>256

7 (100)
0
2–4

7 (100)
0.5–1

7 (100)
0.5–1
Porcine 8 0 8 (100) 4-–>256 2 (25) 6 (75) 2–>32 8 (100) 0.5–1 8 (100) 0.5–1
Bovine 8 7 (88) 1 (12) 1–4 8 (100) 0 2–4 8 (100) 0.5 8 (100) 0.5

*No. (%) Clostidium difficile isolates shown in each interpretive category. S, susceptible; I/R, intermediate or resistant.
†Using moxifloxacin interpretive criteria.

Main Article

Page created: July 12, 2010
Page updated: July 12, 2010
Page reviewed: July 12, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external